2348 On Other Exchanges
2348 is not on other exchanges.

dawnrays pharmaceutical hold (2348) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DAWNRAYS PHARMACEUTICAL HOLD (2348)

Related News

No related news articles were found.

dawnrays pharmaceutical hold (2348) Related Businessweek News

No Related Businessweek News Found

dawnrays pharmaceutical hold (2348) Details

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. The company operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. It offers cephalosporin antibiotics, including intermediates, bulk medicines, and powder for injections; and specific medicines comprising therapeutic areas for anti-HBV, anti-allergic, cardiovascular system, digestive system, urinary system, and endocrine system with dosage forms of tablets, capsules, and granules, as well as midbody. The company was founded in 1995 and is headquartered in Wanchai, Hong Kong. Dawnrays Pharmaceutical (Holdings) Limited is a subsidiary of Fortune United Group Limited.

887 Employees
Last Reported Date: 03/24/17
Founded in 1995

dawnrays pharmaceutical hold (2348) Top Compensated Officers

Co-Founder and Chairman
Total Annual Compensation: CNY885.0K
Co-Founder and Executive Director
Total Annual Compensation: CNY545.0K
Executive Director
Total Annual Compensation: CNY545.0K
Compensation as of Fiscal Year 2015.
dawnrays pharmaceutical hold
Dawnrays Pharmaceutical (Holdings) Limited Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2016

Dawnrays Pharmaceutical (Holdings) Limited announced audited consolidated earnings results for the year ended December 31, 2016. For the period, the company revenue of RMB 824,351,000 against RMB 985,000,000 a year ago. Profit before tax was RMB 333,299,000 against RMB 377,189,000 a year ago. Profit attributable to owners of the parent was RMB 265,917,000 or RMB 0.3312 per diluted share against RMB 302,198,000 or RMB 0.3747 per diluted share a year ago. During the year, the net cash flows from operating activities was approximately RMB 320,258,000 compared to RMB 298,322,000 a year ago. The reasons for the decrease in turnover mainly attributed to the decrease in sales volume of intermediates and bulk medicines and temporary impact caused by the Group's termination of Master Agency Agreement for 0.5 mg Leiyide and withdrawal of goods from the general agency. Such decrease was primarily attributable to the temporary impact caused by termination of Master Agency Agreement for 0.5mg Leiyide, one of the system specific medicines, and withdrawal of goods from the general agency.

Dawnrays Pharmaceutical (Holdings) Limited Recommends the Payment of Final Dividend for the Year Ended 31 December 2016 Payable on 13 June 2017

The Board of Dawnrays Pharmaceutical (Holdings) Limited recommended the payment of a final dividend of HKD 0.10 per share for the year ended 31 December 2016, amounting to the total sum of approximately HKD 80,109,000 to the shareholders whose names appeared in the register of members as of 31 May 2017 subject to the approval of the shareholders at the 2017 Annual General Meeting to be held on 25 May 2017, is to be payable on 13 June 2017 to shareholders.

Dawnrays Pharmaceutical (Holdings) Limited to Report Fiscal Year 2016 Results on Mar 24, 2017

Dawnrays Pharmaceutical (Holdings) Limited announced that they will report fiscal year 2016 results on Mar 24, 2017


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

2348 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2348.
View Industry Companies

Industry Analysis


Industry Average

Valuation 2348 Industry Range
Price/Earnings 11.2x
Price/Sales 3.4x
Price/Book 2.0x
Price/Cash Flow 11.1x
TEV/Sales 2.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DAWNRAYS PHARMACEUTICAL HOLD, please visit www.dawnrays.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.